focus -WSS

focus

author：fashion 2025-10-02 10:38:49 - browse：14646

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： YouTube cracks down on misinformation on cancer treatment

focus

WSS

Montana youths win climate lawsuit against state for promoting fossil fuels

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Illumina slashes 2023 revenue projections yet again

Surge in Apellis stock fueled by confidence in safety of its eye drug

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Affirmative action in medical school literally saved lives

Timeline: How the deadly wildfires took over Maui day by day

United colonoscopy coverage change 'may cost lives,' doctors say

Illumina slashes 2023 revenue projections yet again

Affirmative action in medical school literally saved lives

Dozens dead from Maui wildfires: What we know about the victims

Medical leaders decry Supreme Court decision on affirmative action

Patients, digital health players weigh in on FTC's data privacy plan

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Hospitals are dialing back on venture capital investing

leisure time

Europe is fastest

Teacher posts viral 'school supply rant' with advice for parents

Senators push IRS to launch nonprofit hospital probe

Biogen’s boardroom scandal saddles CEO with first crisis

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

hotspot

entertainment

focus

leisure time